The 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014): A Bridge to a Consensus on HCC Management, Taipei, Taiwan, July 11-13, 2014

Therapeutic targeting of pre-leukemic stem cells (pre-LSCs) may be a viable strategy to eradicate residual disease and prevent leukemia relapse. Now in Cell Stem Cell, Cai et al. (2015) show that loss-of-function mutations in RUNX1 reduce ribosome biogenesis and provide pre-LSCs a selective advantage over normal hematopoietic cells through increased stress resistance.